(Q44316468)

1 December 2017

title

Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome (English)

1 reference

1 December 2017

D Kunkel

1

1 reference

1 December 2017

B Basseri

2

1 reference

1 December 2017

K Low

3

1 reference

1 December 2017

S Lezcano

4

1 reference

1 December 2017

E E Soffer

5

1 reference

1 December 2017

J L Conklin

6

1 reference

1 December 2017

R Mathur

7

1 reference

1 December 2017

M Pimentel

8

1 reference

1 December 2017

publication date

10 May 2011

1 reference

Neurogastroenterology and Motility

1 December 2017

published in

1 reference

1 December 2017

volume

23

1 reference

1 December 2017

issue

8

1 reference

1 December 2017

page(s)

739-e328

1 reference

Four years of North American registry home parenteral nutrition outcome data and their implications for patient management

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

The ileal brake--inhibition of jejunal motility after ileal fat perfusion in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

The ileal brake: a fifteen-year progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

Effect of intestinal resection on human small bowel motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

Exenatide: a novel approach for treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

Is glucagon-like peptide 1 an incretin hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

Biological actions and therapeutic potential of the glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

Glucagon-like peptide-2: update of the recent clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2011.01723.X

10.1111/J.1365-2982.2011.01723.X

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference